Literature DB >> 21529930

Concerns about injectable naltrexone for opioid dependence.

Daniel Wolfe1, M Patrizia Carrieri, Nabarun Dasgupta, Alex Wodak, Robert Newman, R Douglas Bruce.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21529930     DOI： 10.1016/S0140-6736(10)62056-9

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  14 in total

1.  Challenges to implementing opioid substitution therapy in Ukrainian prisons: Personnel attitudes toward addiction, treatment, and people with HIV/AIDS.

Authors:  Maxim Polonsky; Lyuba Azbel; Jeffrey A Wickersham; Faye S Taxman; Evgeny Grishaev; Sergey Dvoryak; Frederick L Altice
Journal:  Drug Alcohol Depend       Date:  2014-12-22       Impact factor: 4.492

2.  Attitudes Toward Addiction, Methadone Treatment, and Recovery Among HIV-Infected Ukrainian Prisoners Who Inject Drugs: Incarceration Effects and Exploration of Mediators.

Authors:  Maxim Polonsky; Julia Rozanova; Lyuba Azbel; Chethan Bachireddy; Jacob Izenberg; Tetiana Kiriazova; Sergii Dvoryak; Frederick L Altice
Journal:  AIDS Behav       Date:  2016-12

3.  Initiation of extended release naltrexone (XR-NTX) for opioid use disorder prior to release from prison.

Authors:  Peter D Friedmann; Donna Wilson; Randall Hoskinson; Michael Poshkus; Jennifer G Clarke
Journal:  J Subst Abuse Treat       Date:  2017-04-19

4.  Review of Case Narratives from Fatal Overdoses Associated with Injectable Naltrexone for Opioid Dependence.

Authors:  Roxanne Saucier; Daniel Wolfe; Nabarun Dasgupta
Journal:  Drug Saf       Date:  2018-10       Impact factor: 5.606

5.  Commentary on Ajazi et al (2021) Re-analysis of the X:BOT Trial.

Authors:  Joshua D Lee; Edward V Nunes; Patricia Novo; Jeanine May; Abigail Matthews; Paul Van Veldhuisen; Robert Lindblad; David Liu; John Rotrosen
Journal:  J Addict Med       Date:  2022 Jul-Aug 01       Impact factor: 4.647

6.  NIDA Clinical Trials Network CTN-0051, Extended-Release Naltrexone vs. Buprenorphine for Opioid Treatment (X:BOT): Study design and rationale.

Authors:  Joshua D Lee; Edward V Nunes; Patricia Novo Mpa; Genie L Bailey; Gregory S Brigham; Allan J Cohen; Marc Fishman; Walter Ling; Robert Lindblad; Dikla Shmueli-Blumberg; Don Stablein; Jeanine May; Dagmar Salazar; David Liu; John Rotrosen
Journal:  Contemp Clin Trials       Date:  2016-08-10       Impact factor: 2.226

7.  Extended-Release Naltrexone Improves Viral Suppression Among Incarcerated Persons Living With HIV With Opioid Use Disorders Transitioning to the Community: Results of a Double-Blind, Placebo-Controlled Randomized Trial.

Authors:  Sandra A Springer; Angela Di Paola; Marwan M Azar; Russell Barbour; Breanne E Biondi; Maureen Desabrais; Thomas Lincoln; Daniel J Skiest; Frederick L Altice
Journal:  J Acquir Immune Defic Syndr       Date:  2018-05-01       Impact factor: 3.731

8.  Ethical and clinical safety considerations in the design of an effectiveness trial: A comparison of buprenorphine versus naltrexone treatment for opioid dependence.

Authors:  Edward V Nunes; Joshua D Lee; Dominic Sisti; Andrea Segal; Arthur Caplan; Marc Fishman; Genie Bailey; Gregory Brigham; Patricia Novo; Sarah Farkas; John Rotrosen
Journal:  Contemp Clin Trials       Date:  2016-09-28       Impact factor: 2.226

Review 9.  The effectiveness of compulsory drug treatment: A systematic review.

Authors:  D Werb; A Kamarulzaman; M C Meacham; C Rafful; B Fischer; S A Strathdee; E Wood
Journal:  Int J Drug Policy       Date:  2015-12-18

10.  Epidemiologic and molecular pathophysiology of chronic opioid dependence and the place of naltrexone extended-release formulations in its clinical management.

Authors:  Albert Stuart Reece
Journal:  Subst Abuse       Date:  2012-09-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.